This article has been updated to clarfiy that although OICR is providing funding for the PRECISE trial, it is not funding 3D Signatures' participation in the initaive. 

NEW YORK (GenomeWeb) – 3D Signatures announced today that its blood-based genome biomarker tests will be used in a clinical study of prostate cancer biopsy methods being run by the Canadian Urology Research Consortium (CURC).

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.